Comparative Pharmacology
Head-to-head clinical analysis: AMIKIN versus GENTAMICIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIKIN versus GENTAMICIN.
AMIKIN vs GENTAMICIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis.
Binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis; bactericidal against gram-negative aerobes.
15 mg/kg/day IV or IM divided every 8 to 12 hours; usual adult dose: 15 mg/kg/day
5-7 mg/kg/day IV or IM in divided doses every 8 hours; for serious infections, up to 5 mg/kg/day IV in 3 divided doses.
None Documented
None Documented
2-3 hours in adults with normal renal function; prolonged to 30-90 hours in ESRD.
Clinical Note
moderateGentamicin + Digoxin
"The serum concentration of Digoxin can be decreased when it is combined with Gentamicin."
Clinical Note
moderateGentamicin + Digitoxin
"The serum concentration of Digitoxin can be decreased when it is combined with Gentamicin."
Clinical Note
moderateGentamicin + Deslanoside
"The serum concentration of Deslanoside can be decreased when it is combined with Gentamicin."
Clinical Note
moderateGentamicin + Acetyldigitoxin
2-3 hours in adults with normal renal function; prolonged to 24-48 hours in anuria; adjust dosing based on renal function.
Renal: >90% unchanged in urine via glomerular filtration; biliary/fecal: <1%.
Primarily renal (glomerular filtration): 90-95% unchanged in urine over 24 hours; biliary/fecal: <2%.
Category C
Category D/X
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic
"The serum concentration of Acetyldigitoxin can be decreased when it is combined with Gentamicin."